.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC23_Cilostazol.Cilostazol

Information

Cilostazol is a phosphodiesterase III inhibitor used primarily as an antiplatelet and vasodilator agent to improve symptoms of intermittent claudication in patients with peripheral arterial disease. It is approved in multiple countries for this indication but has some restrictions due to cardiovascular risk.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.

References

1. Yoo, HD, et al., & Lee, YB (2010). Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. British journal of clinical pharmacology 69(1) 27–37. DOI:10.1111/j.1365-2125.2009.03558.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20078610

2. Shen, Y, et al., & Lou, H (2021). A new simple method for quantification of cilostazol and its active metabolite in human plasma by LC-MS/MS: Application to pharmacokinetics of cilostazol associated with CYP genotypes in healthy Chinese population. Biomedical chromatography : BMC 35(10) e5150–None. DOI:10.1002/bmc.5150 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33894005

3. Lee, HI, et al., & Lee, SY (2018). Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. European journal of clinical pharmacology 74(11) 1417–1426. DOI:10.1007/s00228-018-2522-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30039199

Revisions

• 06/2025 initial generated model